在儿科恶性瘤中开发ATR抑制剂的途径:加速的多利益相关者分析
Susanne A Gatz1,2, Julia Glade-Bender3, Andrew D J Pearson4
1Department of Cancer and Genomic Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
JCO precision oncology
|January 15, 2026
概括
患有DNA复制应激的儿科癌症可能会受益于阿塔克西亚电链切割和Rad3相关蛋白 (ATR) 抑制剂. 战略规划对于开发这些针对儿童的向疗法至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童恶性瘤经常表现出高DNA复制压力和DNA损伤反应 (DDR) 途径缺陷,呈现出治疗脆弱性.
- ATAXIA telangiectasia和Rad3相关蛋白 (ATR) 是DDR通路的关键调节者,使其成为一个有吸引力的治疗点,特别是在组合疗法中.
- 在儿童癌症中ATR抑制剂的最佳开发策略与成人适用不同.
研究的目的:
- 建议在儿科恶性瘤中为阿塔克西亚 (ataxia telangiectasia) 和Rad3相关蛋白 (ATR) 抑制剂提供最佳的发展途径.
- 为了识别特定的儿童癌症,ATR抑制剂可以提供最大的益处.
- 概述儿童瘤学中ATR抑制剂的有效临床试验设计和组合策略.
主要方法:
- 召开了多方利益相关者会议,包括儿科瘤学和药物开发专家.
- 对ATR抑制剂和儿科恶性瘤的现有数据进行了全面的审查和分析.
- 综合发现,提出战略发展途径,包括试验设计和组合方法.
主要成果:
- 对于ATR抑制剂的初步评估应集中于因高复制应激和DDR缺陷而导致的尤宁肉瘤,骨肉瘤和神经母细胞瘤.
- 早期阶段试验应该是代的,以假设为导向的,并纳入对响应者和非响应者的详细分子分析.
- 推的组合包括PARP抑制剂,抗体-药物结合物与拓酶I有效载荷,ALK抑制剂 (针对特定的神经母细胞瘤亚型) 和极光A激酶抑制剂.
- 强调需要早期监管互动,并在监管批准的,学术赞助的,行业支持的平台试验中进行试验.
结论:
- ATAxia telangiectasia和Rad3相关蛋白 (ATR) 抑制剂代表了儿童群体向治疗开发的原型.
- 意识到ATR抑制剂在儿童中的潜力,需要学术界,工业界,监管机构和患者倡导者之间的战略合作.
- 对于成功的ATR抑制剂在儿科癌症的临床开发,一个明确的,协作策略是必不可少的.
相关概念视频
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K